TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenax Therapeutics Inc (TENX) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators are bullish and analysts have a positive outlook with a significant price target increase, the lack of recent news, financial data, and congress trading activity, combined with neutral hedge fund and insider sentiment, suggests a cautious approach. The stock may have potential, but it does not present a compelling entry point for a beginner investor seeking long-term stability.
The technical indicators for TENX are bullish. The MACD is positive and expanding, the RSI is neutral at 69.918, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 12.017), with a current price of 12.1. However, the stock's chance of significant short-term gains is moderate, with a 30% chance to gain 2.95% in the next day and 2.16% in the next month.
Piper Sandler raised the price target from $20 to $50, maintaining an Overweight rating. The firm believes the Phase 3 LEVEL topline results in Q3 2026 are likely to succeed, which could drive share gains.
No significant recent news or event-driven catalysts. Hedge funds and insiders are neutral with no significant trading trends. The lack of congress trading data and financial performance details limits the ability to assess the company's current financial health.
No financial data available for the latest quarter.
Analyst Yasmeen Rahimi from Piper Sandler has raised the price target to $50 from $20 and maintains an Overweight rating. The analyst is optimistic about the company's upcoming Phase 3 trial results in Q3 2026 but notes some investor hesitancy due to the binary risk.
